Go Deep
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 14,649 | -21.0 | 9.09 | 0.06 | 1,380.89 |
| Oct 2026 | 14,836 | -20.6 | 8.90 | 0.06 | 1,349.20 |
| Oct 2026 | 14,508 | -21.6 | 9.22 | 0.06 | 1,397.83 |
| Oct 2026 | 15,214 | -19.7 | 8.53 | 0.06 | 1,290.02 |
| Oct 2026 | 14,836 | -20.6 | 8.90 | 0.06 | 1,347.34 |
| Oct 2026 | 14,419 | -21.5 | 9.31 | 0.06 | 1,408.97 |
| Oct 2026 | 14,594 | -21.2 | 9.16 | 0.06 | 1,382.79 |
| Oct 2026 | 14,901 | -20.5 | 8.86 | 0.06 | 1,334.69 |
| Oct 2026 | 14,933 | -20.4 | 8.83 | 0.06 | 1,335.48 |
Iovance Biotherapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 99,313,000.0 | 71,430,000.0 | 86,771,000.0 | 67,455,000.0 |
| Net Profit | -47,315,000.0 | -79,045,000.0 | -71,904,000.0 | -91,253,000.0 |
| EPS | -0.1 | -0.2 | -0.2 | -0.2 |
Iovance Biotherapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 263,502,000.0 | 164,070,000.0 | 1,189,000.0 | 0.0 | — |
| Net Profit | -390,978,000.0 | -372,177,000.0 | -444,037,000.0 | -395,893,000.0 | — |
| EPS | -1.1 | -1.3 | -1.9 | -2.5 | — |
Iovance Biotherapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 913,170,000.0 | 910,426,000.0 | 780,351,000.0 | 663,982,000.0 | — |
| Total Liabilities | 214,587,000.0 | 200,021,000.0 | 195,738,000.0 | 164,344,000.0 | — |
| Total Equity | 698,583,000.0 | 710,405,000.0 | 584,613,000.0 | 499,638,000.0 | — |
Owes vs Owns
Iovance Biotherapeutics, Inc. owed $0.20 for every $1 it owned in Jun 2026, down from $0.25 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.20× | 0.23× | 0.22× | 0.25× | 0.25× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Iovance Biotherapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 32.5%Receivables 9.0%Inventory 5.7%Fixed assets (tangible) 19.4%Intangible assets 30.6%Other assets 2.8%
How it's funded — Dec 2025
Long-term debt 4.9%Payables 2.4%Other liabilities 16.1%Shareholders' equity 76.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 297.0 | 323.8 | 279.9 | 471.8 |
| Receivables | 82.4 | 69.3 | 0.2 | 0.0 |
| Inventory | 51.7 | 51.5 | 10.4 | 0.0 |
| Fixed assets (tangible) | 177.0 | 164.3 | 176.5 | 178.2 |
| Intangible assets | 279.3 | 282.4 | 229.3 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 25.7 | 19.1 | 84.2 | 13.9 |
| Liabilities & equity | ||||
| Short-term debt | 1.0 | 12.9 | 7.8 | 12.6 |
| Long-term debt | 44.4 | 1.0 | 1.0 | 1.0 |
| Payables | 22.2 | 27.5 | 33.1 | 26.6 |
| Other liabilities | 147.0 | 158.6 | 153.8 | 124.2 |
| Shareholders' equity | 698.6 | 710.4 | 584.6 | 499.6 |
| Net tangible assets | 419.3 | 428.0 | 355.4 | 499.6 |
Iovance Biotherapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -302,408,000.0 | -352,977,000.0 | -361,820,000.0 | -292,757,000.0 | — |
| Investing Activities | 47,496,000.0 | -96,411,000.0 | -155,242,000.0 | 256,455,000.0 | — |
| Financing Activities | 300,773,000.0 | 390,664,000.0 | 462,959,000.0 | 190,150,000.0 | — |